Sentien is a private, preclinical stage regenerative medicine company that is developing cell based therapies for critical care. Their lead product is being developed to treat severe Acute Kidney Injury, (AKI), the sudden loss of kidney function that can occur after cardiac surgery. Sentien has received numerous SBIR awards from the U.S. National Institutes of Health (NIH), including a $3M Phase IIB grant to advance the technology into a Phase I clinical trial.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/10/15 | undisclosed | Series A |
Boehringer Ingelheim Venture Fund Portage Biotech | undisclosed |
